One lincRNA PCA3-based test (the PROGENSA PCA3 assay approved by the FDA) has been used as a marker for the detection of prostate cancers (Evaluation of Genomic Applications in Practice and Prevention [EGAPP] Working Group, 2014). Here, PCA3 is linked to prostate carcinoma.